Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| FoRx Therapeutics | Basel | Series A | $50.0M | 2025-12-18 |
| FundaMental Pharma | Heidelberg | Seed | $2.9M | 2024-04-11 |
| CatalYm | Planegg | Series D | $150.0M | 2024-07-16 |
| Lemonaid Health | San Francisco | Series B | $36.8M | 2020-07-31 |
| Binx Health | Boston | Series F | $65.0M | 2024-04-02 |
| Twentyeight-Seven Therapeutics | Cambridge | Series A | $15.0M | 2019-05-09 |
| Rhygaze | Basel | Series A | $86.0M | 2025-01-10 |
| Aravax | Melbourne | Series B | $22.2M | 2024-01-23 |
8 rows of the CSV in 5 of its 18 columns.
- The 20 Novartis Venture Fund portfolio companies have raised $1.5B in total.
- 2 of them closed their most recent round in the last 12 months, $50.0M combined.
- The largest of those rounds is FoRx Therapeutics' $50.0M Series A, dated December 2025.
- EQT Life Sciences is an investor in 3 of them, more than any other fund.
- Health care is the most common sector, with 17 companies (85%).
- 15% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 11 to 50 employees (47% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
10 of 20| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| Rhygaze | Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. | Biotech | Basel, Switzerland | Series A | $86.0M | 2025-01-10 | $97.3M | Google Ventures, F-Prime, ARCH Venture Partners +2 | 11 to 50 | 2024 |
| CatalYm | CatalYm develops immunotherapies to treat cancer. | Biotech | Planegg, Germany | Series D | $150.0M | 2024-07-16 | $260.9M | Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 | 11 to 50 | 2016 |
| FundaMental Pharma | FundaMental Pharma is a neuroscience company with preclinical-stage drug candidates. | Biotech | Heidelberg, Germany | Seed | $2.9M | 2024-04-11 | $13.3M | HTGF (High-Tech Gruenderfonds), Novartis Venture Fund, coparion +2 | 1 to 10 | 2016 |
| Aravax | Aravax is an early stage biotechnology company developing a treatment for peanut allergy. | Biotech | Melbourne, Australia | Series B | $22.2M | 2024-01-23 | Novartis Venture Fund, Breakthrough Victoria, Uniseed +2 | 11 to 50 | 2015 | |
| Hyku | Hyku develops covalent drugs that precisely target disease-causing proteins. | Biotech | Lexington, United States | Seed | $56.0M | 2023-09-19 | $56.0M | KB Investment, RA Capital Management, Novartis Venture Fund +2 | 11 to 50 | 2021 |
| Covagen | Covagen develops protein-based therapeutics for inflammatory diseases and cancer. | Biotech | Schlieren, Switzerland | Series B | $66.1M | 2013-12-09 | Ventech, Novartis Venture Fund, Andera Partners +2 | 11 to 50 | 2007 | |
| Okairos | Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. | Biotech | Basel, Switzerland | Series B | $20.5M | 2010-09-14 | $30.1M | EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 | 1 to 10 | 2007 |
| ESBATech | ESBATech develops fully human antibody fragments for therapeutic applications using the single-chain antibody framework. | Biotech | Schlieren, Switzerland | Series B | $22.0M | 2008-08-07 | Novartis Venture Fund, VI Partners, SV Health Investors +2 | 51 to 100 | 1998 | |
| Roche Glycart | Roche Glycart researches, develops, and commercializes antibody-based biotechnology products. | Biotech | Schlieren, Switzerland | Series A | $13.6M | 2003-11-26 | $13.6M | Forbion Capital Partners, Novartis Venture Fund, BioMedPartners +1 | 101 to 250 | 2000 |
Table 1. Novartis Venture Fund portfolio companies: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 20.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
Table 2. Novartis Venture Fund portfolio companies: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 3 | 15% | 1 | FoRx Therapeutics |
| 2 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 3 | 15% | ||
| 3 | Versant Ventures | Venture capital firm | Menlo Park, United States | 3 | 15% | ||
| 4 | BioGeneration Ventures | Micro VC fund | Naarden, The Netherlands | 2 | 10% | ||
| 5 | OrbiMed | Private equity firm | New York, United States | 2 | 10% | ||
| 6 | BioMedPartners | Venture capital firm | Basel, Switzerland | 2 | 10% | ||
| 7 | Pfizer | Corporate venture arm | New York, United States | 1 | 5% | 1 | FoRx Therapeutics |
| 8 | Pfizer Venture Investments | Corporate venture arm | New York, United States | 1 | 5% | 1 | FoRx Therapeutics |
| 9 | Omega Funds | Secondary purchaser | Boston, United States | 1 | 5% | 1 | FoRx Therapeutics |
| 10 | Thuja Capital | Startup accelerator | Utrecht, The Netherlands | 1 | 5% | ||
| 11 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 1 | 5% | ||
| 12 | coparion | Startup accelerator | Cologne, Germany | 1 | 5% | ||
| 13 | Bioqube Ventures | Venture capital firm | Hasselt, Belgium | 1 | 5% | ||
| 14 | Bayern Kapital | Venture capital firm | Landshut, Germany | 1 | 5% | ||
| 15 | Civilization Ventures | Venture capital firm | San Francisco, United States | 1 | 5% |
Table 3. Novartis Venture Fund portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 17 | 85% | $1.4B |
| Biotech | 15 | 75% | $1.1B |
| Software | 4 | 20% | $245.8M |
| Artificial intelligence | 2 | 10% | $71.5M |
| Hardware | 2 | 10% | $15.7M |
Table 4. Novartis Venture Fund portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Novartis Venture Fund portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| Switzerland | 9 | 45% |
| United States | 5 | 25% |
| Germany | 2 | 10% |
| China | 2 | 10% |
| Australia | 1 | 5% |
| United Kingdom | 1 | 5% |
Table 6. Novartis Venture Fund portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Basel | 3 | 15% |
| Schlieren | 3 | 15% |
| Heidelberg | 1 | 5% |
| Planegg | 1 | 5% |
| San Francisco | 1 | 5% |
| Boston | 1 | 5% |
| Cambridge | 1 | 5% |
| Melbourne | 1 | 5% |
| Lexington | 1 | 5% |
| Falmer | 1 | 5% |
| Shenzhen | 1 | 5% |
| Yangzhou | 1 | 5% |
Table 7. Novartis Venture Fund portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| March 2026 | 1 | 50% | |
| December 2025 | 1 | 50% | $50.0M |
Table 8. Novartis Venture Fund portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 1 | 5% | |
| 2025 | 3 | 15% | $136.0M |
| 2024 | 5 | 25% | $273.2M |
| 2023 | 1 | 5% | $56.0M |
| 2020 | 1 | 5% | $36.8M |
| 2019 | 1 | 5% | $15.0M |
Table 9. Novartis Venture Fund portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 5% |
| 2020 to 2022 | 2 | 10% |
| 2015 to 2019 | 6 | 30% |
| 2010 to 2014 | 2 | 10% |
| Before 2010 | 9 | 45% |
Table 10. Novartis Venture Fund portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 3 | 16% |
| 11 to 50 | 9 | 47% |
| 51 to 100 | 3 | 16% |
| 101 to 250 | 3 | 16% |
| 501 to 1,000 | 1 | 5% |
Table 11. Novartis Venture Fund portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Novartis Venture Fund is recorded as one of its investors. On 16 November 2026 that is 20 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 10 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 20 rows: 3 have no round amount, 0 no city and 3 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Novartis Venture Fund portfolio companies are on the list?
- 20, in the file dated 16 November 2026. 2 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 20 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.